CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing Probody® therapeutics for cancer treatment. The company engages in the research and development of biologic therapeutics that activate specifically in the tumor microenvironment. CytomX has multiple Probody® candidates in clinical trials and preclinical research phases. Its operations primarily serve the oncology market, with a commitment to advancing safer and more effective cancer therapies.
